Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid

  • Mauro Betelli Medicina Generale, Bolognini Hospital, ASST Bergamo Est, Seriate, Italy
  • Fabio De Stefano Medicina Generale, Bolognini Hospital, ASST Bergamo Est, Seriate, Italy
  • Alberto Tedeschi Medicina Generale, Bolognini Hospital, ASST Bergamo Est, Seriate, Italy

Keywords

COVID-19, ruxolitinib, Janus kinase inhibitors

Abstract

We describe the case of a patient hospitalized for the second time in a month due to delayed worsening of lung lesions in COVID-19 infection without bacterial superinfection. He was treated with hydroxychloroquine, IV dexamethasone and ruxolitinib with rapid improvement of respiratory failure; 1 month after the second discharge, maintaining low-dose oral prednisone, lung consolidations were significantly reduced on control CT.

VIEW THE ENTIRE ARTICLE

References

Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 2020; 31(5): 454-470.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–407.

Portsmore S, Tran Nguyen TN, Beacham E, Neelakantan P. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. Br J Haematol 2020;190(4):525–528.

Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol. Front Med (Lausanne) 2020;7:466.

La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 2020;34(7):1805–1815.

Published: 2020-10-14

Issue: Vol 7 No 11 (view)

Section: Articles

How to cite:
1.
Betelli M, De Stefano F, Tedeschi A. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid. EJCRIM 2020;7 doi:10.12890/2020_001938.